Currently, research into preventing and treating CMS involves understanding the biomarkers (such as adipokines, or inflammatory and oxidative stress markers), personalised medicine (using genetic data), lifestyle interventions, and even pharmacological treatments such as Metformin. However, greater research is needed into understanding this condition and its relation to NAFLD in a nuanced manner. Specific populations, such as certain ethnic groups, socioeconomic backgrounds or environmental factors need to be explored. This will ensure for a deeper understanding of this risk factor for NAFLD. This review by Khan AR et al. aimed to discuss the current understanding and treatment of CMS, a risk factor of NAFLD.
Overall, CMS is a condition which increases the risk of NAFLD in individuals. Further research is needed into understanding this condition to ensure that the path to NAFLD is understood more comprehensively, and better treatments are develop for both.